PMC/PubMed Indexed Articles
Indexed In
- Academic Journals Database
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- Scimago
- Ulrich's Periodicals Directory
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- MIAR
- University Grants Commission
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Enhancing Vaccine Efficacy with Adenoviral Vectors: From Gene Delivery Systems to Therapeutic Vaccine Development
4th International conference on Vaccines, Vaccination and Immunization
August 18-19, 2023 | Webinar
Anis H. Khimani, Christian Thirion
Ralf Wagner, Peter Johannes Holst USA
Scientific Tracks Abstracts: Journal of Vaccines & Vaccination
Abstract:
Recombinant adenoviral vectors have been used as gene delivery or expression vehicles in multiple therapeutic applications such as gene therapy, vaccines, or CRISPR. In vaccine research and development, gene expression via adenoviral vector constructs have been shown to be effective in enhancing T-cell responses against several viral infections or endogenous viruses causing malignancy. We will present data from novel therapeutic vaccine candidates based on the hAd19a/64 vector designed to target an extended set of antigens to fight diseases such as HPV induced cervical and oropharyngeal cancers. Furthermore, in combination with chemotherapeutic drugs, the vaccine effect was enhanced. In addition to elicitation of CD4+ and CD8+ T-cells reported from prior research, in our studies the effect of the novel vaccine and chemotherapeutic drug resulted in an increased infiltration of dendritic cells into the tumor. Design and development of the novel vaccine candidate with extended antigen repertoire within adenoviral backbone will be presented.
Biography :
Anis is Senior Strategy Leader, as part of the Life Sciences segment strategy team at PerkinElmer. He has prior academic and postdoctoral research background in molecular biology, viral pathogenesis, viral vector development, and vaccine studies from Harvard Medical School and Dana-Farber Cancer Institute, followed by research and development in genomics and assay development at PerkinElmer. Subsequently, his focus has been in product management, business development, and strategy. Dr. Khimani also has industry research experience from the British multinational pharma, The Boots Pharmaceutical Company. He has authored and co-authored numerous publications, chapters, review articles, abstracts, and has been invited to present talks at national and international conferences.